The Cigna Group
CI
$279.72
+1.83%
The Cigna Group is a leading integrated health services organization operating in the Healthcare sector, specifically within Medical - Healthcare Plans. Its core business encompasses pharmacy benefit management (PBM) and specialty pharmacy services, delivered through its Evernorth segment, alongside health insurance and benefits offerings via its Cigna Healthcare division. The company is a dominant player in the managed care and PBM landscape, distinguished by its scale and the strategic integration of services following its 2018 merger with Express Scripts. The current investor narrative is shaped by its recent financial performance, including a significant revenue increase in its latest quarter, and ongoing institutional confidence as evidenced by a series of analyst reiterations of Buy or Overweight ratings in early 2026, suggesting a focus on execution and stability in a complex regulatory environment.…
CI
The Cigna Group
$279.72
Investment Opinion: Should I buy CI Today?
Rating: Hold. The core thesis is that CI presents a classic value trap—deeply undervalued on traditional metrics but facing significant fundamental headwinds that justify the market's skepticism, requiring clear evidence of margin stabilization before a bullish stance is warranted. This aligns with the analyst community's bullish ratings but acknowledges the stock's persistent negative price action.
The stock trades at a compelling forward P/E of 8.34x and a P/S of 0.27, which are deeply discounted versus sector averages, suggesting significant embedded pessimism. Furthermore, the company generates robust free cash flow ($8.39B TTM) and maintains a reasonable debt load (D/E 0.75). However, these positives are counterbalanced by severe margin compression (Q4 gross margin down 219 bps YoY) and a 1-year price decline of -15.6% that dramatically underperforms the market.
The thesis would upgrade to a Buy if CI demonstrates consecutive quarters of gross margin stabilization or expansion above 8%, or if the forward P/E compresses further below 7x without a deterioration in the growth outlook. It would downgrade to a Sell if revenue growth decelerates below 5% YoY or if net margins contract below 1.5%. Relative to its history and the challenges it faces, the stock is fairly valued at current levels—the low price reflects the real risks, leaving little margin for error.
Sign up to view all
CI 12-Month Price Forecast
CI is a battleground stock where compelling valuation (P/E 8.34x, P/S 0.27) clashes with deteriorating profitability metrics. The low beta and strong cash flow provide a defensive floor, but the path to a sustained rally requires a clear reversal in margin trends, which has not yet materialized. The base case of range-bound trading is most likely, with the stock oscillating between its value support and growth/margin ceiling. The stance would upgrade to bullish on evidence of sequential margin improvement for two consecutive quarters. It would turn bearish if revenue growth stalls below 5% while margins continue to contract, validating the bear case.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cigna Group's 12-month outlook, with a consensus price target around $363.64 and implied upside of +30.0% versus the current price.
Average Target
$363.64
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$224 - $364
Analyst target range
Analyst coverage for Cigna is limited in the provided dataset, with only 5 analysts contributing to estimates for revenue and EPS. While a specific consensus price target and recommendation breakdown are not provided, the institutional ratings data shows a clear pattern of bullish sentiment, with multiple firms including Barclays, Truist Securities, and Guggenheim reiterating Buy or Overweight ratings in early 2026. This suggests the analyst community leans bullish, viewing recent performance or prospects favorably. The estimated revenue range for the coming period is wide, from a low of $325.60 billion to a high of $345.08 billion, with an average of $331.74 billion. A wide target range often signals higher uncertainty regarding future performance, which could relate to variables like medical cost trends, PBM contract renewals, or regulatory changes. The series of reiterated positive ratings in Q1 2026, without downgrades, indicates sustained institutional confidence despite the stock's weak price action, potentially viewing the current valuation as an attractive entry point.
Bulls vs Bears: CI Investment Factors
The bull case for CI is anchored in its deeply discounted valuation, strong cash generation, and defensive profile, which create a compelling value proposition. The bear case focuses on severe margin pressure, overwhelming dependence on a low-margin PBM business, and persistent negative price momentum that reflects deep-seated investor concerns. Currently, the bearish evidence from price action and margin trends appears stronger in the near term, overshadowing the attractive valuation. The single most important tension in the investment debate is whether the company can stabilize or improve its profitability margins. If CI can demonstrate margin resilience, the current valuation discount presents a significant opportunity. If margins continue to compress, the low P/E multiple may be justified, and the stock could remain in a value trap.
Bullish
- Deeply Discounted Valuation: CI trades at a forward P/E of 8.34x and a P/S ratio of 0.27, both significantly below typical healthcare plan sector averages. This valuation compression, with the stock near its 52-week low, prices in significant pessimism and offers a substantial margin of safety for value investors.
- Q4 2025 revenue grew 10.4% YoY to $72.5B, driven by the dominant Evernorth PBM segment ($64.7B). The company's massive scale, including key contracts like the Department of Defense, provides a durable competitive moat and a stable revenue base.
- Robust Free Cash Flow Generation: The company generates substantial cash, with TTM free cash flow of $8.39 billion. This strong cash flow supports a healthy balance sheet (D/E of 0.75), funds shareholder returns, and provides flexibility for strategic investments or M&A.
- Analyst Confidence Amid Weakness: Multiple institutional firms (Barclays, Truist, Guggenheim) reiterated Buy or Overweight ratings in early 2026. This sustained bullish sentiment from analysts, despite the stock's -15.6% 1-year price decline, suggests they view the current price as an attractive entry point based on fundamentals.
Bearish
- Severe Margin Compression: Q4 2025 gross margin fell to 7.66%, down from 9.85% a year ago, and net margin compressed to 1.70% from 2.17%. This pressure on profitability, despite strong revenue growth, raises concerns about the sustainability of earnings and the low-margin nature of the PBM business.
- Persistent Negative Price Momentum: The stock is down 15.6% over the past year, drastically underperforming the SPY's 34.9% gain. Trading at just 35% of its 52-week range ($239.51-$350), it shows deep negative momentum and a lack of investor confidence requiring a fundamental catalyst to reverse.
- Overwhelming Segment Dependence: The Evernorth PBM segment generated $64.74B of the total $72.47B Q4 revenue (89%). This extreme concentration creates significant risk if the PBM business faces pricing pressure, regulatory changes, or contract losses, with the smaller Cigna Healthcare segment ($12.51B) unable to offset a major decline.
- High Short Interest & Skepticism: A short ratio of 3.61 indicates elevated bearish bets against the stock. This high level of short interest reflects market skepticism about the company's near-term prospects and can act as a technical overhang, potentially amplifying selling pressure.
CI Technical Analysis
The stock is in a pronounced downtrend over the past year, with a 1-year price change of -15.60%, significantly underperforming the SPY's 34.9% gain. As of the latest close at $278.64, the price is trading at approximately 35% of its 52-week range, calculated from a low of $239.51 to a high of $350.00, positioning it much closer to its annual lows. This suggests the stock is in a deep value territory but also reflects persistent negative momentum and investor skepticism, requiring a fundamental catalyst for a sustained reversal. Recent short-term momentum shows signs of a tentative recovery, with a 1-month gain of 5.30% and a 3-month gain of 2.36%, both positive yet still lagging the broader market's performance over the same periods. This divergence, where short-term momentum is positive against a starkly negative long-term trend, could signal either a technical oversold bounce or the early stages of a potential trend reversal, contingent on fundamental improvements. Key technical levels are clearly defined, with major support at the 52-week low of $239.51 and resistance at the 52-week high of $350.00. A decisive break above the recent trading range would be needed to signal a shift in sentiment, while a breakdown below support could trigger further declines. The stock exhibits low market-correlated volatility, with a beta of 0.272, indicating it is approximately 73% less volatile than the SPY, which is atypical for a healthcare stock and may reflect its defensive characteristics or limited speculative interest.
Beta
0.27
0.27x market volatility
Max Drawdown
-28.1%
Largest decline past year
52-Week Range
$240-$350
Price range past year
Annual Return
-16.9%
Cumulative gain past year
| Period | CI Return | S&P 500 |
|---|---|---|
| 1m | +5.2% | +8.5% |
| 3m | +0.2% | +2.8% |
| 6m | -7.3% | +4.6% |
| 1y | -16.9% | +32.3% |
| ytd | +0.2% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CI Fundamental Analysis
Cigna's revenue trajectory is robust, with Q4 2025 revenue of $72.47 billion representing a 10.39% year-over-year growth. This acceleration is evident when comparing to the prior-year Q4 revenue of $65.65 billion, and the sequential trend from Q1 2025 ($65.50B) to Q4 shows consistent quarterly increases. The growth is overwhelmingly driven by the Evernorth (PBM) segment, which contributed $64.74 billion in the latest period, vastly overshadowing the Cigna Healthcare segment's $12.51 billion, highlighting the company's dependence on its pharmacy services arm. The company is profitable but with compressed margins in the latest quarter; Q4 2025 net income was $1.23 billion on a gross margin of 7.66%, which is down significantly from the 9.85% gross margin in Q4 2024. The net margin for the quarter was 1.70%, also lower than the 2.17% from a year ago, indicating pressure on profitability despite top-line growth, a trend that requires monitoring for sustainability. The balance sheet is solid with a manageable debt-to-equity ratio of 0.75, and the company generates substantial cash, evidenced by a trailing twelve-month free cash flow of $8.39 billion. The current ratio of 0.85 suggests adequate but not excessive short-term liquidity, while a return on equity (ROE) of 14.28% demonstrates reasonable efficiency in generating profits from shareholder equity, supporting the company's ability to fund operations and shareholder returns internally.
Quarterly Revenue
$72.5B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.07%
Latest Quarter
Free Cash Flow
$8.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CI Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. Cigna trades at a trailing PE of 12.29x and a forward PE of 8.34x based on estimated EPS. The notable discount of the forward multiple implies the market expects earnings growth, aligning with analyst EPS estimates averaging $45.90 for the coming period. Compared to sector averages, Cigna's valuation appears discounted; its trailing PE of 12.29x is below typical healthcare plan multiples, and its Price-to-Sales (PS) ratio of 0.27 is exceptionally low, signaling the market is assigning a low multiple to its revenue base, possibly due to margin concerns or the low-margin nature of its PBM business. Historically, the stock's own valuation has compressed; its current trailing PE of 12.29x is below its recent historical range seen in the provided data (e.g., 14.83x at end of Q4 2025 and higher in prior quarters). Trading near the lower end of its own historical valuation band suggests the market has priced in significant pessimism, presenting a potential value opportunity if the company can demonstrate margin stability or growth acceleration to justify a re-rating.
PE
12.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -94x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on profitability and business concentration. The sharp compression in Q4 2025 gross margin (7.66% vs. 9.85% YoY) and net margin (1.70% vs. 2.17%) indicates significant operational pressure, potentially eroding earnings growth despite a 10.4% revenue increase. The company's revenue is overwhelmingly concentrated in the Evernorth PBM segment (89% of Q4 revenue), creating vulnerability to contract losses, regulatory changes targeting drug pricing, or intensified competition in the PBM space. While the balance sheet is solid (D/E 0.75) and free cash flow is strong ($8.39B TTM), earnings volatility, as seen in quarterly net income fluctuations, adds uncertainty to the investment case.
Market & Competitive Risks are highlighted by valuation compression and sector-specific headwinds. The stock's trailing P/E of 12.29x is below its own historical range and likely below sector peers, but this discount may persist if margin concerns are not alleviated. The healthcare sector faces ongoing regulatory scrutiny, particularly around pharmacy benefit manager practices and drug pricing transparency, which could impact CI's core PBM profitability. The stock's low beta (0.272) suggests it is defensive but also indicates limited speculative interest or growth expectations from the market, potentially capping multiple expansion.
Worst-Case Scenario involves a combination of continued margin erosion, a major PBM contract loss (e.g., the Department of Defense renewal issues), and a broader market downturn that further compresses valuations for value stocks. In this adverse scenario, the stock could re-test its 52-week low of $239.51, representing a downside of approximately -14% from the current price of $278.64. A more severe bear case, factoring in a further de-rating of its already low multiples, could see a decline towards the -28% max drawdown level observed in the data, implying a potential loss in the range of -14% to -28% for investors from the current price.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: Continued compression of gross and net margins, as seen in Q4 2025 (gross margin fell to 7.66%), which directly threatens earnings. 2) Business Concentration Risk: Over 89% of quarterly revenue comes from the Evernorth PBM segment, making the company vulnerable to contract losses or regulatory changes in that specific business. 3) Sentiment & Momentum Risk: The stock has underperformed the SPY by over 50 percentage points in the past year, and high short interest (short ratio 3.61) creates a technical overhang. 4) Regulatory Risk: The PBM industry faces ongoing political and regulatory scrutiny that could impact pricing models and profitability.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $285 and $310, as steady revenue growth is offset by persistent margin concerns, keeping valuation multiples depressed. The Bull Case (25% probability) projects a rise to $330-$350, driven by margin recovery and a valuation re-rating. The Bear Case (15% probability) warns of a decline to $240-$260 if margins worsen or growth disappoints. The base case is most likely, implying limited near-term upside from the current ~$278 price until there is clearer evidence of fundamental improvement. The key assumption is that margin pressure stabilizes but does not significantly reverse.
CI appears significantly undervalued based on traditional absolute and relative metrics. It trades at a forward P/E of 8.34x and a Price-to-Sales ratio of 0.27, which are well below typical averages for the healthcare plans sector. Historically, its own trailing P/E of 12.29x is also below its recent range. The market is paying a deep discount, which implies expectations of stagnant growth, further margin compression, or both. Therefore, the stock is undervalued statistically, but this discount reflects real and substantial fundamental concerns that must be resolved for the valuation to normalize.
CI is a good buy for a specific type of investor: the patient value investor seeking a deeply discounted, cash-generative company in a defensive sector. With a forward P/E of 8.34x and a P/S of 0.27, the valuation is compelling and offers a significant margin of safety. However, it is not a good buy for growth-oriented investors or those sensitive to near-term price volatility, given its 15.6% decline over the past year and ongoing margin pressures. The biggest risk is that the low valuation becomes a 'value trap' if profitability does not improve. A good entry point would be on further weakness towards the $260 support level.
CI is more suitable for a long-term investment horizon (3+ years) rather than short-term trading. Its low beta (0.272) means it lacks the volatility typically desired for short-term trades, and the catalyst for a re-rating—margin improvement—may take several quarters to materialize. Long-term investors can collect the 2.2% dividend yield while waiting for the operational story to potentially improve. The stock's value characteristics and defensive nature align with a buy-and-hold strategy where an investor is betting on a gradual corporate turnaround or a mean reversion in valuation over years, not months.
